A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
Professor James Paton, Director of the University of Adelaide’s Research Centre for Infectious Diseases and his team have been working on a vaccine for Streptococcus pneumoniae (the pneumococcus) that could save two million lives globally a year and address the overuse of antibiotics that leads to resistance.
“The pneumococcus is the biggest bacterial killer on the planet. It’s the most common cause of pneumonia, which is responsible for about 20 per cent of deaths from all causes in children under 5 years in developing countries. Globally, the pneumococcus accounts for about two million deaths a year,” says Professor Paton.
Streptococcus pneumoniae, which is principally spread through close contact with infected but asymptomatic carriers, is the leading cause of sinus and ear infections, meningitis, sepsis and pneumonia. Ear infections are one of the most common childhood illnesses that are habitually treated with antibiotics, contributing to increasing bacterial resistance.
“Vaccinating people against Streptococcus pneumoniae would help to ameliorate the global challenge of increasing bacterial resistance to antibiotics,” says Professor Paton.
“The problem with the existing pneumococcal vaccine is that it targets the outside coat of complex carbohydrates – of which there are 98 structurally distinct types. The current vaccine costs about $150 a dose and only covers 13 types.
“What we have done is to remove this coat to expose all the surface proteins that are common to all pneumococcal types. The body mounts an immune response to these surface proteins if previously exposed or vaccinated.”
Sixteen months ago, Adelaide-based GPN Vaccines Pty Ltd was created to develop this novel “whole bacterial” vaccine (Gamma-PNTM) against Streptococcus pneumoniae. The company has already secured investment from local angel investors as well as a major grant from the National Health & Medical Research Council and a Commercialisation grant from the South Australian Government.
GPN Vaccines has now raised a further AUS$1.1 million from international and Australian-based investors that will be used for preclinical evaluation of the Gamma-PNTM vaccine. Toxicity tests will be carried out as well as the scale-up clinical grade manufacture of the vaccine in readiness for testing in a first-in-human clinical trial.
Learn more: STEP FORWARD FOR PNEUMONIA VACCINE DEVELOPMENT
The Latest on: Pneumonia
via Google News
The Latest on: Pneumonia
- New Antibiotic Treats Pneumonia, Skin Infections on February 6, 2019 at 4:38 pm
Omadacycline, a revamped, "modernized" version of tetracycline, is aimed at people who get sick out in the real world -- not the seriously ill hospital patient whose infection may resist many ... […]
- Omadacycline for Bacterial Pneumonia on February 6, 2019 at 2:13 pm
The authorized source of trusted medical research and education for the Chinese-language medical community. The New England Journal of Medicine The most trusted, influential source of new medical know... […]
- 'I feel like I failed': Father distraught after 4-year-old daughter dies from flu, pneumonia on February 6, 2019 at 9:59 am
A Texas family is mourning the loss of a 4-year-old girl who died from the flu and pneumonia. According to KTRK, Ashanti Grinage began showing symptoms last Tuesday, went to the emergency room and sta... […]
- ‘We Didn’t Know’: Heartbroken Texas Dad Warns Other Parents After 4-Year-Old Daughter Dies of Flu, Pneumonia on February 6, 2019 at 8:11 am
A heartbroken Texas father is talking about his daughter’s death to warn other parents about the dangers of the flu and pneumonia in children. Martel Grinage told television station WFAA in ... […]
- Ventilator-associated Pneumonia Market Driven by Growing Prevalence of Lung Diseases Says MRFR| Analysis till 2023 on February 5, 2019 at 11:04 pm
Market Research Future (MRFR) has announced a new release on the global ventilator-associated pneumonia market. The report takes into account the global ventilator-associated pneumonia market’s histor... […]
- Father devastated after 4-year-old daughter dies of flu, pneumonia on February 5, 2019 at 5:36 pm
GARLAND, Texas – A heartbroken Texas father is talking about his daughter’s death to warn other parents about the dangers of the flu and pneumonia in children. Martel Grinage told WFAA that ... […]
- Breakthrough A.I.-powered stethoscope diagnoses pneumonia like a robot doctor on February 5, 2019 at 12:06 pm
Pneumonia, an acute respiratory condition which affects the lungs, kills millions of people around the world each year. This includes 16 percent of all children who die under the age of five. It’s par... […]
- 4-year-old Texas girl dies of flu, pneumonia days after exhibiting first symptoms on February 5, 2019 at 8:33 am
A 4-year-old girl died of complications from the flu and pneumonia just four days after she began to exhibit any signs of illness, according to her devastated family. Ashanti Grinich, of Garland, Texa... […]
- Family devastated after 4-year-old girl dies from flu, pneumonia on February 5, 2019 at 7:55 am
A family is mourning the loss of their 4-year-old daughter who died from the flu and pneumonia in Garland, Texas. Ashtani Grinage is the first child flu-related death of the season in Dallas County. S... […]
- 4-year-old Texas girl dead from pneumonia and flu complications just four days after symptoms on February 5, 2019 at 3:05 am
A 4-year-old Texas girl with a 103-degree fever died suddenly from complications from pneumonia and the flu. Ashanti Grinich of the Dallas suburb of Garland was taken to the emergency room on Jan. 27 ... […]
via Bing News